CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP
· Real-Time Price · USD
37.76
-0.49 (-1.28%)
At close: May 05, 2025, 3:59 PM
37.57
-0.50%
After-hours: May 05, 2025, 07:59 PM EDT
-1.28% (1D)
| Bid | 27.26 |
| Market Cap | 3.26B |
| Revenue (ttm) | 36.62M |
| Net Income (ttm) | -366.25M |
| EPS (ttm) | -4.34 |
| PE Ratio (ttm) | -8.7 |
| Forward PE | -9.32 |
| Analyst | Buy |
| Ask | 48.3 |
| Volume | 1,114,218 |
| Avg. Volume (20D) | 2,241,621 |
| Open | 37.95 |
| Previous Close | 38.25 |
| Day's Range | 37.50 - 38.42 |
| 52-Week Range | 30.04 - 67.88 |
| Beta | 1.84 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglo...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 19, 2016
Employees 393
Stock Exchange NASDAQ
Ticker Symbol CRSP
Website https://www.crisprtx.com
Analyst Forecast
According to 19 analyst ratings, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $82, which is an increase of 117.16% from the latest price.
Stock ForecastsNext Earnings Release
CRISPR Therapeutics AG is scheduled to release its earnings on May 16, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+14.33%
CRISPR Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago
+9.29%
CRISPR Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results and Barclays raised its price target on the stock from $55 to $56.
